Baxter International Inc. (BAX) earnings on July 30, 2026

BAX price around the earnings

26.75

Change: +8.0%

Start of the measured window End of the measured window

24.76 26.39 28.01 29.64 24.77

July 30, 2026

Price: green if it ends above the starting price; red if it ends below
Start of the measured window
End of the measured window
Market open
Starting price

Price series around the event

Prior thesis

Prior outlook: Pessimistic Outcome: Missed

Thesis published: 2026-07-30, 09:59 UTC
Results released: 2026-07-30, 11:15 UTC

Strong recent trend (+12.5% 30d) but analyst hold (-7.3% upside); 50% beat rate mixed; crowding risk elevated.

Context analyzed before publication

Trend: Trajectory collapsed from 16.1 to -53.5 signaling major divergence; strong recent trend contradicts negative analyst consensus.

Analysts

Evidence

Analyst consensus: Hold
Consensus average (1-5): 2.85
Analysts covering the stock: 12
Average price target: 22.96
Lowest price target: 17
Highest price target: 40
Upside to price target: -7.3%
Revenue growth: 2.9%
Forward EPS: 2
Trailing EPS: -1.94
Analyst moves in the last 60 days: 5

Strong buy: 0
Buy: 2
Hold: 11
Sell: 1
Strong sell: 0

Strong buy: 0
Buy: 2
Hold: 11
Sell: 1
Strong sell: 0

July 28, 2026 · UBS: Maintains rating (Neutral → Neutral)
July 28, 2026 · Stifel: Maintains rating (Hold → Hold)
July 27, 2026 · TD Cowen: Maintains rating (Hold → Hold)
July 15, 2026 · Goldman Sachs: Maintains rating (Neutral → Neutral)
July 6, 2026 · Evercore ISI Group: Maintains rating (Outperform → Outperform)

News and sentiment

Evidence

Sentiment

Sentiment: Constructive
Mention volume: Low
Normalized volume: 33%

News

Sources (5)

UBS Maintains Neutral on Baxter International, Raises Price Target to $25 (opens in a new tab) — Benzinga
Stifel Maintains Hold on Baxter International, Raises Price Target to $24 (opens in a new tab) — Benzinga
TD Cowen Maintains Hold on Baxter International, Raises Price Target to $24 (opens in a new tab) — Benzinga
Goldman Sachs Maintains Neutral on Baxter International, Raises Price Target to $21 (opens in a new tab) — Benzinga
Evercore ISI Group Maintains Outperform on Baxter International, Raises Price Target to $24 (opens in a new tab) — Benzinga

Technicals

Evidence

Price when the context was analyzed: 24.76
Average true range (ATR): 3.4%
Distance to 52-week high: -10.9%
14-day change (14d): +11.8%
30-day change (30d): +12.5%
30-day relative strength: +14.0%
SPY change (30d): -1.5%
Nearest support: 24.55
Distance to nearest support: 0.9%
Nearest resistance: 24.88
Distance to nearest resistance: 0.5%
Volume accumulation ratio (14d / 46d): 0.95

Mid: 24.55 (0.9% away, 0.26 ATR, 15 touches)
Mid: 24.24 (2.1% away, 0.63 ATR, 17 touches)
Mid: 23.95 (3.3% away, 0.98 ATR, 6 touches)

Mid: 24.88 (0.5% away, 0.15 ATR, 7 touches)
Minor: 26.25 (6% away, 1.8 ATR, 2 touches)
Minor: 26.78 (8.2% away, 2.43 ATR, 2 touches)

Trends

Evidence

Average earnings surprise: +2.6%

April 30, 2026: actual EPS 0.36 vs estimate 0.31 (surprise +15.9%)
February 12, 2026: actual EPS 0.44 vs estimate 0.54 (surprise -17.8%)
October 30, 2025: actual EPS 0.69 vs estimate 0.6 (surprise +15.4%)
July 31, 2025: actual EPS 0.59 vs estimate 0.61 (surprise -3.3%)

Expected move

Implied move: +11.5%
Source: Options chain

Reactions over its last 20 earnings

Median move: 6%
75th percentile move: 9%
90th percentile move: 14.6%
Up / down moves: 6 / 14
Average up move: +4.6%
Average down move: -8.3%

Monitoring and close

What Baxter International Inc. reported

Status: Finished

Actual EPS	0.54
EPS estimate	0.37
EPS surprise	+45.9%
Revenue	$2,960 million
Revenue estimate	$2,795 million
Revenue surprise	+5.9%

Baxter beat Q2 estimates and raised 2026 outlook. Shares rose 17%, reflecting optimism on turnaround progress despite margin pressure.

Sources (13)

BAX Stock Gains on Q2 Earnings & Sales Beat, Margins Contract (opens in a new tab) — Zacks
Baxter’s shares soar by 17% after reporting positive Q2 (opens in a new tab) — Medical Device Network
Baxter Jumps After Q2 Beat, Boosted 2026 Guidance Reflects Turnaround Progress (opens in a new tab) — Benzinga
Baxter (BAX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (opens in a new tab) — Zacks
Baxter (NYSE:BAX) Reports Upbeat Q2 CY2026, Stock Jumps 16.1% (opens in a new tab) — StockStory
Baxter International (BAX) Surpasses Q2 Earnings and Revenue Estimates (opens in a new tab) — Zacks
Baxter International (NYSE:BAX) Jumps After Q2 Earnings Beat and Raised Outlook (opens in a new tab) — ChartMill
Baxter International Inc. (BAX) Q2 2026 Earnings Call Transcript (opens in a new tab) — SeekingAlpha
Baxter International Raises FY2026 Adj EPS Guidance from $1.85-$2.05 to $1.95-$2.15 vs $1.91 Est; Raises FY2026 Sales Guidance from $11.244B-$11.356B to $11.581B-$11.694B vs $11.357B Est (opens in a new tab) — Benzinga
Baxter beat expectations with adjusted EPS of $0.54 and revenue of $2.960B. — Benzinga
Baxter Intl Q2 Adj. EPS $0.54 Beats $0.37 Estimate, Sales $2.960B Beat $2.795B Estimate (opens in a new tab) — Benzinga
Baxter Reports Second-Quarter 2026 Results (opens in a new tab) — Yahoo
Baxter International Inc. 2026 Q2 - Results - Earnings Call Presentation (opens in a new tab) — SeekingAlpha

Pre-market second reading after the results

Verdict: Beat expectations

Heading into the open, results beat expectations on both earnings and revenue and the price is indicating +14.3% pre-market, a move above the stock's usual reaction (about 6%). The figures overturn the prior pessimistic scenario. Across our market history, in the 1,045 similar cases the close held that direction 96% of the time.

How the stock reacted

Outcome: Missed
Consolidated: +8.0%
Max favorable move (MFE): 0%
Max adverse move (MAE): 21.1%